Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment

By M. Volkova, R. Russell. Current Cardiology Reviews, 2011

824 citations recorded by the source corpus.

Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.

Subfields: Biophysics, Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/0f32d5af713533100123d9f4b47e6d426b7b5823